Changes in Hong Kong stocks | Genting Xinyao (01952) rose more than 5% in early trading, Starbitol's application for the marketing of a new drug with PSVT indications was approved in China

The Zhitong Finance App learned that Genting Xinyao (01952) rose more than 5% in early trading. As of press release, it rose 4.73% to HK$32.78, with a turnover of HK$151 million.

According to the news, on September 3, Genting Xinyao announced that the National Drug Administration (NMPA) has approved the New Drug Marketing License Application (NDA) for Starbital® (etripamil nasal spray) to treat acute episodes of paroxysmal supraventricular tachycardia (PSVT) in adults, which reverted to sinus rhythm.

Starbitol was approved by the US Food and Drug Administration (FDA) in December 2025, making it the first and only innovative treatment approved for the treatment of acute episodes of PSVT in adults in more than 30 years. This approval in China means that this innovative treatment has officially entered the Chinese market, becoming Genting Xinyao's first approved product in the field of cardiovascular disease.